FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
The histone deacetylase inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor –positive, HER2-negative, advanced breast cancer in a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - January 11, 2021 Category: Pharmaceuticals Source Type: news

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. (Source: Roche Media News)
Source: Roche Media News - January 11, 2021 Category: Pharmaceuticals Source Type: news

Margetuximab for HER2+ Metastatic Breast Cancer Falls Short Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
With such a small improvement in progression-free survival, margetuximab is'simply not enough'for advanced HER2+ breast cancer, says Dr Kathy Miller.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Advances in HER2+ MBC From SABCS 2020 Advances in HER2+ MBC From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2+ metastatic breast cancer, including gains in progression-free survival in patients with brain metastases.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Highlights in Metastatic Breast Cancer From SABCS 2020 Highlights in Metastatic Breast Cancer From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2- metastatic breast cancer, including updates on immunotherapy and promising results for a novel oral taxane.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news

Margetuximab Approved for HER2+ Metastatic Breast Cancer Margetuximab Approved for HER2+ Metastatic Breast Cancer
A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 16, 2020 Category: Drugs & Pharmacology Source Type: news

Effect of BMI on Treatment Response in HER2 Breast Cancer Effect of BMI on Treatment Response in HER2 Breast Cancer
Is there an association between obesity and treatment response? A study examined the potential impacts of BMI among breast cancer patients receiving neo-adjuvant anti-HER2 therapies.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

What Does It Mean to Have HER2-Positive Breast Cancer?
HER2, short for human epidermal growth factor receptor 2, describes a protein that plays a role in normal breast cell development. But in some breast cancers, the HER2 gene produces too many proteins. (Source: WebMD Health)
Source: WebMD Health - December 14, 2020 Category: Consumer Health News Source Type: news

RxPONDER: Even More Women May Forgo Chemo for Breast Cancer RxPONDER: Even More Women May Forgo Chemo for Breast Cancer
The first results from RxPONDER provide insight – and controversy – regarding the need for chemotherapy by women with node-positive, low-risk HR+, HER2- breast cancer.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 11, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

PENELOPE-B: Palbociclib Disappoints in HR+, HER2 – Breast Cancer PENELOPE-B: Palbociclib Disappoints in HR+, HER2 – Breast Cancer
The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with HR+, HER2-negative primary breast cancer, according to first results from the PENELOPE-B trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

High-risk, HR+, HER2-, early-stage BC patients continue to benefit from abemaciclib
(American Association for Cancer Research) Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news

Should CTCs Guide Treatment Choice in HR+, HER2 – Breast Cancer? Should CTCs Guide Treatment Choice in HR+, HER2 – Breast Cancer?
Trial results suggest circulating tumor cell (CTC) counts may be a reliable biomarker for guidingfirst-line treatment in patients with HR+, HER2 – metastatic breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Combo HER2 Product Recommended for Approval in EU Combo HER2 Product Recommended for Approval in EU
The combination of pertuzumab and trastuzumab with hyaluronidase (Phesgo) for subcutaneous injection is coming soon to Europe.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

CHMP recommends EU approval of Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 13 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, adm inistered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. Based on this recommendation, a final decision regarding the approval of Phesgo is expected from the European...
Source: Roche Media News - November 13, 2020 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
Basel, 13 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, adm inistered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. Based on this recommendation, a final decision regarding the approval of Phesgo is expected from the European...
Source: Roche Investor Update - November 13, 2020 Category: Pharmaceuticals Source Type: news

New research supports clinical utility of CTC count for metastatic breast cancer
(Dowling& Dennis PR) Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer. Published in the November issue of JAMA Oncology, this is the first study to support clinical utility of CTC count in a randomized clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2020 Category: International Medicine & Public Health Source Type: news

pCR in HER2+ Breast Cancer Predicts Long-Term Survival pCR in HER2+ Breast Cancer Predicts Long-Term Survival
A pathologic complete response to targeted therapy in HER2-positive breast cancer portends good long-term outcomes and may be a marker of cure, according to the final results of a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Induction of phenotypic changes in HER2-postive breast cancer cells
(Impact Journals LLC) The cover for issue 30 of Oncotarget features Figure 4, " RNAseq results demonstrating differences between normal, cancer, and redirected cells, " by Frank-Kamenetskii, et al. which reported that the influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2020 Category: Cancer & Oncology Source Type: news

Abemaciclib Beneficial for HR + , HER2 − Early Breast Cancer
Significant improvements seen in rates of invasive disease - free survival, distant recurrence - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 6, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Abemaciclib Beneficial for HR+, HER2 − Early Breast Cancer
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2020 Category: Pharmaceuticals Source Type: news

Abemaciclib Beneficial for HR & #43;, HER2 & #8722; Early Breast Cancer
TUESDAY, Oct. 6, 2020 -- For patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 −), high-risk early breast cancer (EBC), the addition of abemaciclib to endocrine therapy (ET) increases the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2020 Category: Pharmaceuticals Source Type: news

HER2+ breast cancer patients live longer if drugs given before surgery eradicate tumour
(European Organisation for Research and Treatment of Cancer) Final analysis of results from a randomised clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had no signs of residual disease after treatment survived longer without the cancer returning than patients who did not. This was more likely to happen in patients who received the two anti-cancer drugs together, rather than as single agents. The research is presented at the 12th European Breast Cancer Conference. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

Breast cancer medication risk
(Flinders University) New research led by Flinders University has found a link between beta-blockers and survival outcomes in some breast cancer patients. Beta-blockers, commonly used to manage cardiovascular disease, were negatively associated with survival outcomes in patients with HER2 (Human Epidermal Growth Factor Receptor 2) positive advanced breast cancer, according to a new paper in the Frontiers In Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2020 Category: Cancer & Oncology Source Type: news

Opening an autophagy window as the apoptosis door starts to close
(Tokyo Medical and Dental University) Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death. The antibody-drug conjugate (ADC) selectively targeted HER2-overexpressing cancer calls and reduced cell viability at lower concentrations than free supermolecule drug. It is hoped that the ADC will provide a targeted autophagic death route for treating apoptosis resistant cancer cells in vivo, and ultimately provide an alternate approach in the clinic. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 24, 2020 Category: Biology Source Type: news

Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First new drug in years reduces recurrence in high risk HR+ early breast cancer
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2020 Category: International Medicine & Public Health Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

New therapy targets breast cancer metastases in brain
(Northwestern University) When breast cancer spreads to the brain, the prognosis is grim. Patients only have about six months to live. Women with HER2-positive breast cancer tend to develop brain metastases in up to 55% of cases. Chemotherapy drugs targeting breast cancer cells in the brain aren't effective, because they can't cross the blood-brain-barrier. But a new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in a preclinical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission
Infusion of autologous HER2 CAR T cells after lymphodepleting chemotherapy induced remission in a child with metastatic rhabdomyosarcoma (RMS), researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Investigational breast cancer vaccine plus immune therapy work well in tandem
(Duke University Medical Center) A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 30, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy
Basel, 29 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 - human epidermal growth factor receptor 2 - is an important biomarker sometimes found in breast cancers.2 Its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer. The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, enabl...
Source: Roche Investor Update - July 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy
Basel, 29 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 - human epidermal growth factor receptor 2 - is an important biomarker sometimes found in breast cancers.2 Its detection and inhibition can help healthcare professionals more effectively manage this aggressive cancer. The VENTANA HER2 Dual ISH DNA Probe Cocktail assay is designed to be completed within the same day, enabl...
Source: Roche Media News - July 29, 2020 Category: Pharmaceuticals Source Type: news

Indigenous American Ancestry Tied to HER2 + Breast Cancer
Higher proportion of Indigenous American ancestry associated with a greater incidence of HER2 + breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 28, 2020 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Journal, Source Type: news

Indigenous American Ancestry Tied to HER2+ Breast Cancer
TUESDAY, July 28, 2020 -- Indigenous American (IA) origin could partly contribute to the higher incidence of human epidermal growth factor receptor 2-positive (HER2+) breast cancer in Latinas, according to a study recently published in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2020 Category: Pharmaceuticals Source Type: news

Indigenous American Ancestry Tied to HER2 & #43; Breast Cancer
TUESDAY, July 28, 2020 -- Indigenous American (IA) origin could partly contribute to the higher incidence of human epidermal growth factor receptor 2-positive (HER2+) breast cancer in Latinas, according to a study recently published in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2020 Category: Pharmaceuticals Source Type: news

New MBC Treatments: Triple-Negative; HER2+; and ER+, HER2- New MBC Treatments: Triple-Negative; HER2+; and ER+, HER2-
The latest therapeutic options improve progression-free survival for some patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 16, 2020 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Immunotherapy with CAR T cells results in exceptional patient recovery
(Baylor College of Medicine) In a clinical trial, a child with rhabdomyosarcoma, a form of muscle cancer, that had spread to the bone marrow, showed no detectable cancer following treatment with chimeric antigen receptor (CAR) T cells that were engineered to target the HER2 protein on the surface of the cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2020 Category: Cancer & Oncology Source Type: news

FDA Approves At-Home Treatment For HER2-Positive Breast Cancer
Some breast cancer patients may qualify for a newly-approved at-home treatment. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 1, 2020 Category: Pharmaceuticals Authors: Marla Milling, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Trastuzumab cost effective in HER2-positive metastatic gastric cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2020 Category: Drugs & Pharmacology Source Type: news

Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs
Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home. The drug, branded as Phego, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast cancer. Genentech… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Genentech wins FDA OK for at-home combo of 2 marquee cancer drugs
Genentech Inc. won regulatory approval Monday of a breast cancer treatment that combines Herceptin and Perjeta with an enzyme and can be administered at home. The drug, branded as Phesgo, is the first time South San Francisco-based Genentech has combined two monoclonal antibodies that can be administered by a single injection just under the skin in combination with intravenous chemotherapy. With the enzyme hyaluronidase, it was approved for treatment of early and metastatic HER2-positive breast… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 29, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer
South San Francisco, CA -- June 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 29, 2020 Category: Drugs & Pharmacology Source Type: news